Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06455085 · ClinicalTrials.gov registry record · NA

RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

A NA study of Osteoporosis and Fragility Fracture, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
2,634
Enrollment target
20
Study locations

NCT06455085: Recruiting NA study of Osteoporosis and Fragility Fracture, sponsored by University of Alabama at Birmingham.

NCT06455085 is a NA study of Osteoporosis and Fragility Fracture that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 2,634 participants, above the 1,515-participant average among 84 other Osteoporosis trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06455085, a NA study of Osteoporosis and Fragility Fracture, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
2,634 participants
Enrollment target
20
Study locations

Study Summary

RESTORE tests whether Augmented-FLS, where patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health provider, is better than Enhanced Usual Care, which includes patient and PCP education and activation. We also aim to determine the influence of age, race, ethnicity, sex, poverty level, geographic region, and timing of entry into the trial after a fracture on the effectiveness of the two strategies.

Primary Outcome

Incidence of fracture 24 months post randomization

Interventions

  • BEHAVIORAL Augmented-Fracture Liaison Service Arm
  • BEHAVIORAL Enhanced Usual Care Arm

Study Locations (20)

Illinois

  • Rush University Medical Center - Chicago
  • University of Illinois Chicago (UIC), UI Health - Chicago
  • Loyola University Chicago - Maywood

North Carolina

  • The University of North Carolina at Chapel Hill - Chapel Hill
  • Duke University - Durham
  • Wake Forest University Health Sciences - Winston-Salem

Florida

  • University of Florida- Gainesville - Gainesville
  • University of Florida- Jacksonville - Jacksonville

Missouri

  • Missouri Orthopaedic Institute - Columbia
  • Washington University in St. Louis - St Louis

New York

  • Hospital for Special Surgery - New York
  • Montefiore Medical Center - The Bronx

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic Arizona - Scottsdale

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 2,634 participants
Start Date 2024-12-16
Est. Completion 2029-06-01
Phase NA
University of Alabama at Birmingham

1,160 total trials

What NCT06455085 shows while recruiting

NCT06455085 is an interventional study that assigns participants to a tested intervention. Its 2,634 participants enrollment target places it among the larger protocols in the corpus, above the 1,515-participant average among 84 other Osteoporosis trials with a reported enrollment target (74% higher).

The record links to 3 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Augmented-Fracture Liaison Service Arm is the first listed.

NCT06455085 names 20 study sites across 13 states, led by Illinois, North Carolina, Florida.

Frequently Asked Questions

What is clinical trial NCT06455085 about?

NCT06455085 is a clinical study titled "RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE". RESTORE tests whether Augmented-FLS, where patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health provider, is better than Enhanced Usual Care, which includes patient and PCP education and activation. We also aim to determine the influence of age, race, ...

What is the current status of trial NCT06455085?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,634 participants. The study started on 2024-12-16. Estimated completion is 2029-06-01.

What conditions does trial NCT06455085 study?

This clinical trial studies the following conditions: Osteoporosis, Fragility Fracture, Osteoporotic Fractures.

What interventions are being tested in trial NCT06455085?

The interventions under investigation include: Augmented-Fracture Liaison Service Arm (BEHAVIORAL), Enhanced Usual Care Arm (BEHAVIORAL).

Who is sponsoring clinical trial NCT06455085?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06455085 being conducted?

This trial has 20 study locations across Alabama, Arizona, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06455085's enrollment target sits among peer trials

2,634 7th of 84 higher than 78 of 84 other Osteoporosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06825715 · 2,653 participants · NA

    Multilevel Intervention for Precision Oncology

  • NCT06033950 · 2,600 participants · Phase 3

    A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

  • NCT06574672 · 2,600 participants · NA

    Embedded Palliative Care in the MICU

  • NCT05471908 · 2,674 participants · NA

    Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06455085, the US trial registry maintained by the National Library of Medicine. NCT06455085 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.